首页> 外文期刊>Endocrine journal >Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adrenal incidentaloma
【24h】

Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adrenal incidentaloma

机译:肾上腺偶发瘤相关亚临床库欣综合征的诊断标准

获取原文
           

摘要

References(32) Cited-By(13) Subclinical Cushing’s syndrome (SCS) associated with adrenal incidentaloma is usually characterized by autonomous cortisol secretion without overt symptoms of Cushing’s syndrome (CS). Although the diagnostic criteria for SCS differ among countries, the 1 mg dexamethasone suppression test (DST) is essential to confirm the presence and the extent of cortisol overproduction. Since 1995, SCS has been diagnosed in Japan based on serum cortisol levels ≥3 μg/dL (measured by radioimmunoassay [RIA]) after a 1 mg DST. However, the increasing use of enzyme immunoassays (EIA) instead of RIA has hindered the diagnosis of SCS because of the differing sensitivities of commercially available assays, particularly for serum cortisol levels of around 3 μg/dL. One way to overcome this problem is to lower the cortisol threshold level after a 1 mg DST. In the present study, we examined the clinical applicability of lowering the cortisol threshold to 1.8 μg/dL, similar to the American Endocrine Society’s guidelines for CS, by reanalyzing 119 patients with adrenal incidentaloma. Our findings indicate that serum cortisol levels ≥1.8 μg/dL after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level 10 pg/mL (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dL at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.
机译:参考文献(32)被引用者(13)与肾上腺偶发瘤相关的亚临床库欣综合征(SCS)通常以自主皮质醇分泌为特征,而没有库欣综合征(CS)的明显症状。尽管各国对SCS的诊断标准不同,但1 mg地塞米松抑制试验(DST)对于确认皮质醇过量生产的存在和程度至关重要。自1995年以来,日本已根据1毫克DST后血清皮质醇水平≥3μg/ dL(通过放射免疫测定[RIA]测定)诊断出SCS。但是,由于市售检测方法的敏感性不同,特别是对于血清皮质醇水平约为3μg/ dL,越来越多地使用酶免疫测定法(EIA)代替RIA阻碍了SCS的诊断。解决此问题的一种方法是在1 mg DST后降低皮质醇阈值水平。在本研究中,我们通过重新分析119例肾上腺偶发瘤患者,研究了将皮质醇阈值降低至1.8μg/ dL(类似于美国内分泌学会的CS指南)的临床适用性。我们的发现表明,如果同时满足以下两个条件,则在1 mg DST后血清皮质醇水平≥1.8μg/ dL可用于确诊SCS:(1)基础ACTH水平<10 pg / mL(或血浆ACTH反应不良)促肾上腺皮质激素释放激素)和(2)在21:00至23:00 h血清皮质醇≥5μg/ dL。如果仅满足(1)和(2)中的一项,我们建议在SCS的诊断中考虑其他临床特征,包括血清脱氢表雄酮硫酸盐水平,无尿皮质醇水平,肾上腺闪烁显像和临床表现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号